- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06142422
Intermittent Theta Burst Stimulation of the Precuneus (Stim-TISiTBS)
Intermittent Theta Burst Stimulation of the Precuneus for the Treatment of Resistant Schizophrenia
Study Overview
Detailed Description
This is an interventional, prospective, randomized, double-blind, multicenter study, comparing iTBS treatment (experimental group) of the precuneus to placebo stimulation (control group) of patients suffering from resistant schizophrenia and having been exposed to childhood trauma.
The study population will be patients aged 18 to 40 years old exposed to childhood trauma, presenting with schizophrenia resistant to antipsychotic treatments.
This study will be implemented in 4 investigative centers. Each patient will participate for a period of 3 months.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34093
- Clinique Rech
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Right-handed patient aged 18 to 40 years inclusive;
- Patient presenting schizophrenia as defined in the Diagnostic and Statistical Manual-5;
- Patient under antipsychotic treatment in accordance with the recommendations of the High Authority of Health, at a stable dosage and without modification of psychotherapeutic treatment for at least 4 weeks;
- Patient on mono or dual antipsychotic therapy.
- Patient presenting residual symptoms, i.e. absence of remission defined by the criteria of the "Remission criteria of the Schizophrenia Working Group Consensus";
- Patient having been exposed to at least one type of trauma in childhood and having a score higher than the threshold values of the childhood trauma questionnaire: emotional neglect, physical abuse, emotional abuse, physical neglect, sexual abuse;
- Patient having signed an informed consent form to participate in the study.
Exclusion Criteria:
- Patient with a contraindication to magnetic resonance imaging or intermittent Theta Burst Stimulation (presence of a metallic body, pacemaker, implantable defibrillator or other implantable metallic device, epilepsy, stroke or recent head trauma);
- Patient who is not French-speaking or cannot read and write;
- Patient under guardianship;
- Patient in forced care (psychiatric care upon decision of the State representative and psychiatric care at the request of a third party);
- Pregnant woman or likely to be pregnant (of childbearing age) without effective contraception or breastfeeding;
- Patient participating in another clinical trial, or during a period of exclusion from another clinical trial;
- Patient who is not a beneficiary of a social security system.
- Patient who, according to the assessment of the investigator, risks not being compliant or diligent in the study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: experimental group with intermittent Theta Burst Stimulation
The procedure under study is the use of a stimulation device to perform intermittent Theta Burst Stimulation treatment on the precuneus to treat resistant schizophrenia.
Targeting requires a neuronavigation device.
|
The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma. The target is the left precuneus, which is defined by neuronavigation. |
|
Placebo Comparator: control group with placebo stimulation
In the control group, stimulation is simulated using a "Sham" or placebo coil.
The stimulation device is the same as for the experimental group, only the coil differs.
|
The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma. The target is the left precuneus, which is defined by neuronavigation. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
average of the Scale for assessment of negative symptoms/scale for assessment of positive symptoms scale scores
Time Frame: 21 days
|
The Primary Outcome Measure will be assessed by the average of the Scale for assessment of negative symptoms/scale for assessment of positive symptoms scale scores at approximately 21 days compared to the score at inclusion in the two groups.
|
21 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-A01006-39
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
Clinical Trials on stimulation device
-
Andrew KrystalRecruitingBipolar II Disorder, Most Recent Episode Major Depressive | Bipolar II DisorderUnited States
-
Neurolief Ltd.Completed
-
Neurolief Ltd.Terminated
-
EMKinetics, IncTerminated
-
Seoul National University HospitalRecruitingDysphagiaKorea, Republic of
-
Seoul National University HospitalCompleted
-
Northwestern UniversityEvergreen InvitationalCompletedObstetric Anal Sphincter Injury | Vaginal Electrical StimulationUnited States
-
University of ManchesterManchester University NHS Foundation Trust; Firstkind LtdUnknown
-
RML Specialty HospitalCompletedMuscle WeaknessUnited States
-
Imperial College LondonCompleted